PolyPid (PYPD) News Today $3.22 -0.28 (-8.00%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period FY2024 Earnings Estimate for PolyPid Issued By HC WainwrightDecember 21 at 1:37 AM | americanbankingnews.comPolyPid (NASDAQ:PYPD) Earns "Buy" Rating from HC WainwrightDecember 18 at 1:35 AM | americanbankingnews.comPAVmed (NASDAQ:PAVM) and PolyPid (NASDAQ:PYPD) Financial ReviewDecember 17, 2024 | americanbankingnews.comPolyPid’s Strategic Advancements and Clinical Progress: A Buy RecommendationDecember 16, 2024 | markets.businessinsider.comPolyPid announces research, development collaboration with ImmunoGenesisDecember 12, 2024 | markets.businessinsider.comPolyPid (PYPD) Gets a Buy from Craig-HallumDecember 12, 2024 | markets.businessinsider.comPolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer ImmunotherapyDecember 11, 2024 | globenewswire.comPolyPid Ltd.: PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-ComplianceNovember 30, 2024 | finanznachrichten.dePolyPid receives noncompliance notification from NasdaqNovember 29, 2024 | markets.businessinsider.comPolyPid Faces Nasdaq Non-Compliance ChallengeNovember 29, 2024 | tipranks.comPolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-ComplianceNovember 29, 2024 | globenewswire.comPolyPid (PYPD) Gets a Hold from BarclaysNovember 19, 2024 | markets.businessinsider.comPositive Indicators and Financial Stability Support Roy Buchanan’s Optimistic Outlook on PolyPid’s StockNovember 16, 2024 | markets.businessinsider.comPolyPid Reports Q3 Results Amid SHIELD II Trial ProgressNovember 15, 2024 | markets.businessinsider.comPolyPid Announces SHIELD II Trial Progress and FinancialsNovember 14, 2024 | markets.businessinsider.comPolyPid Ltd. (PYPD) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comPolyPid (PYPD) Receives a Buy from Craig-HallumNovember 12, 2024 | markets.businessinsider.comPolyPid Announces $8.25 Million Share Sale PlanNovember 9, 2024 | markets.businessinsider.comPolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select ConferenceNovember 7, 2024 | globenewswire.comCraig-Hallum bullish on PolyPid, initiates with a BuyNovember 6, 2024 | markets.businessinsider.comCraig-Hallum Initiates Coverage of PolyPid (PYPD) with Buy RecommendationNovember 6, 2024 | msn.comPolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024October 30, 2024 | globenewswire.comRosalind Advisors, Inc. Reduces Stake in PolyPid LtdOctober 24, 2024 | finance.yahoo.comPolyPid announces publication in IJS on Phase 3 SHIELD I trial of D-PLEX100October 22, 2024 | markets.businessinsider.comPolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal SurgeryOctober 21, 2024 | globenewswire.comPolyPid retains stock target, buy rating on positive trial enrollment updateOctober 4, 2024 | investing.comPolyPid completes enrollment for phase 3 trialOctober 3, 2024 | uk.investing.comBuy Rating Affirmed for PolyPid on D-PLEX’s Positive Trial Milestones and Commercial ProspectsOctober 3, 2024 | markets.businessinsider.comPolyPid Buy Rating Affirmed: Promising Clinical Trials and Solid Financial OutlookOctober 2, 2024 | markets.businessinsider.comPolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site InfectionsOctober 1, 2024 | globenewswire.comPolyPid to Participate in Three Upcoming Fall Investor ConferencesSeptember 3, 2024 | globenewswire.comPolyPid (PYPD) Receives a Hold from BarclaysAugust 20, 2024 | markets.businessinsider.comPolyPid Ltd (PYPD) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | seekingalpha.comBuy Rating Affirmed for PolyPid Amidst Strong Trial Progress and Robust Financial PositionAugust 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for PolyPid on D-PLEX Clinical Progress and Potential Early ApprovalAugust 16, 2024 | markets.businessinsider.comPolyPid Ltd. (NASDAQ:PYPD) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | insidermonkey.comPolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsAugust 14, 2024 | finance.yahoo.comPolyPid secures $14 million in private placementAugust 4, 2024 | investing.comPolyPid Announces Private Placement for Up to $14 Million in Gross ProceedsAugust 1, 2024 | globenewswire.comPolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024July 31, 2024 | globenewswire.comPolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 TrialJune 10, 2024 | globenewswire.comEarnings call: PolyPid reports progress in D-PLEX100 trial, eyes expansionMay 12, 2024 | investing.comPolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comBuy Rating Affirmed for PolyPid on D-PLEX Progress and Solid Financial FootingMay 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Cartesian Therapeutics (RNAC)May 8, 2024 | markets.businessinsider.comPYPD Stock Earnings: PolyPid Beats EPS for Q1 2024May 8, 2024 | investorplace.comPolyPid Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 8, 2024 | globenewswire.comPolyPid to Participate in Citizens JMP Life Sciences ConferenceMay 1, 2024 | globenewswire.comBuy Rating Affirmed for PolyPid on Strong Trial Progress and Expanding Pipeline PotentialApril 30, 2024 | markets.businessinsider.comPolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site InfectionsApril 30, 2024 | globenewswire.com Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover PYPD Media Mentions By Week PYPD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PYPD News Sentiment▼-0.270.61▲Average Medical News Sentiment PYPD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PYPD Articles This Week▼81▲PYPD Articles Average Week Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bellevue Life Sciences Acquisition News CollPlant Biotechnologies News Spectral AI News Envoy Medical News SurgePays News Beyond Air News NEXGEL News Neuronetics News Precision Optics News IRIDEX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PYPD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PYPD Stock Alerts